REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Sep 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-09-10

Reporting Person: GOLDSTEIN JOSEPH L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-10	Common Stock	M	2479	$380.95	Acquired	8370	Direct
2021-09-10	Common Stock	S	2479	$650.0	Disposed	5891	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-10	Non-Qualified Stock Option (right to buy)	$380.95	M	2479	Disposed	2028-01-02	Common Stock (2479)	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.